RPL17 and nonpapillary renal cell carcinoma: To explore whether an immune escape-associated profile correlates with immunotherapy response, we selected 180 ccRCC patients enrolled in the CHECKMate 025 trial (NCT01668784) who received the immune checkpoint PD-1 inhibitor nivolumab for external validation of our established nomogram (Figure 6A).